Original language | English (US) |
---|---|
Pages (from-to) | 232-233 |
Number of pages | 2 |
Journal | Neurology |
Volume | 71 |
Issue number | 4 |
DOIs | |
State | Published - Jul 22 2008 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Neurology, Vol. 71, No. 4, 22.07.2008, p. 232-233.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Translating research into treatments
AU - Noseworthy, John H.
AU - Gross, Robert A.
AU - Engel, Andrew G.
AU - Johnston, Karen C.
AU - Knopman, David S.
AU - Mink, Jonathan W.
AU - Ransohoff, Richard M.
AU - Uitti, Ryan J.
N1 - Funding Information: Richard M. Ransohoff, MD , conducts research supported by the NIH, the National MS Society, the Dana Foundation, and the Nancy Davis Center without Walls. Dr. Ransohoff has received fees for pre-clinical consulting from Amgen, Astra-Zeneca, Biogen-Idec, Boehringer Ingelheim, Merck, Merck-Serono, Merrimack, Millennium, Momenta, Novartis, Novimmune, Pharmacopeia, Schering-Plough, Vertex, and Xanthus. Dr. Ransohoff serves on the Immunology/Inflammation subgroup of Vertex Pharmaceuticals Incorporated's Scientific Advisory Board, the ChemoCentryx Scientific Advisory Board, and a Safety Evaluation Committee for Merck. Funding Information: Jonathan W. Mink, MD, PhD , has received funding from the NIH and is on the medical advisory board of the Batten Disease Support and Research Association, the Scientific Advisory Board of Tourette Syndrome Association, and the Medical Advisory Board of the Pediatric Neurotransmitter Disease Association. Funding Information: Robert A. Gross, MD, PhD, FAAN , has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past 5 years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. Dr. Gross has served on the speakers' bureaus for Abbott, UCB, Ortho-McNeil, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Funding Information: Ryan J. Uitti, MD, FAAN , has received funding from the NIH, Pacific Alzheimer Research Foundation, and Advanced Neuromodulation Systems. Funding Information: Andrew G. Engel, MD, FAAN , receives research funding from the NIH and from the Muscular Dystrophy Association.
PY - 2008/7/22
Y1 - 2008/7/22
UR - http://www.scopus.com/inward/record.url?scp=50549095773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50549095773&partnerID=8YFLogxK
U2 - 10.1212/01.wnl.0000314830.63429.a1
DO - 10.1212/01.wnl.0000314830.63429.a1
M3 - Editorial
C2 - 18525031
AN - SCOPUS:50549095773
SN - 0028-3878
VL - 71
SP - 232
EP - 233
JO - Neurology
JF - Neurology
IS - 4
ER -